AC
MRNA icon

Abbrea Capital’s Moderna MRNA Stock Holding History

Abbrea Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,760
Closed -$507K – 239
2024
Q1 		$507K Buy
4,760
+1,200
+34% +$121K 0.07% 161
2023
Q4 		$354K Buy
3,560
+1,275
+56% +$107K 0.05% 189
2023
Q3 		$236K Sell
2,285
-19
-0.8% -$2.12K 0.04% 210
2023
Q2 		$280K Sell
2,304
-23
-1% -$3.07K 0.04% 200
2023
Q1 		$357K Hold
2,327
– – 0.06% 180
2022
Q4 		$418K Sell
2,327
-107
-4% -$17.5K 0.08% 164
2022
Q3 		$288K Hold
2,434
– – 0.05% 185
2022
Q2 		$348K Hold
2,434
– – 0.06% 173
2022
Q1 		$419K Hold
2,434
– – 0.06% 174
2021
Q4 		$618K Buy
2,434
+19
+0.8% +$5.55K 0.08% 155
2021
Q3 		$929K Sell
2,415
-500
-17% -$184K 0.14% 116
2021
Q2 		$685K Sell
2,915
-100
-3% -$17.9K 0.1% 144
2021
Q1 		$395K Buy
+3,015
New +$437K 0.07% 170

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Abbrea Capital's MRNA Position: Q2 2024 in Review

Abbrea Capital sold out of Moderna (MRNA) in Q2 2024, closing a stake of 4,760 shares — an estimated $507K sold.

Abbrea Capital first reported a position in MRNA in Q1 2021 and held it in 13 quarters. The position peaked at $929K in Q3 2021. 955 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Abbrea Capital reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Abbrea Capital sold 4,760 Moderna shares in Q2 2024, an estimated $507K.
  • Abbrea Capital first reported a position in Moderna in Q1 2021 and held it in 13 quarters.
  • Abbrea Capital's Moderna position peaked at $929K in Q3 2021.
  • 955 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.